What You Should Know:
- Exai Bio and researchers at UCSF released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and smallest tumor sizes.
- Earlier detection of breast cancer is crucial for optimal patient outcomes but cannot always be achieved based on symptoms or mammography.
Non-Invasive Blood-Based Platform Delivers Promising Data on Detecting Breast Cancer At It’s Earliest Stages
Exai Bio is a
Read More
dna
How AI-Based Drug Repurposing Could Help Prevent Repetitive Behavior Disorders
Repetitive behavioral disorders such as obsessive-compulsive disorder (OCD), Tic Disorder and Tourette Syndrome have been challenging to treat because they involve considerable complexity. For example, the symptoms of one disorder can vary among individuals as does the coexistence or non-existence of other behavior disorders such as anxiety and depression. Further, the treatment of OCD, Tic Disorder and Tourette Syndrome varies depending on
Read More
What Has COVID Ever Done For Us? Here 9 Examples
The early 2020s will be studied by historians as a time of global uncertainty when an unknown pathogen caused a public health emergency that brought the world to the brink.
It may also be remembered as a time of unparalleled cooperation and advancement in technologies, prompted by the Covid pandemic, that provided enduring benefits for generations to come.
Just as the two world wars of the 20th Century were the deadliest and most attritional in history, they also triggered developments in
Read More
HLTH22 Day 3 News Summary
DispatchHealth Raises $330M for Hospital-at-Home Care
DispatchHealth, a provider of in-home medical care raises $330M led by Optum Ventures with support from current investors such as Humana (NYSE: HUM), Oak HC/FT, Echo Health Ventures and Questa Capital. New investors included Adams Street Partners, the Olayan Group, Silicon Valley Bank, Pegasus Tech Ventures and Blue Shield of California. Patients and their care partners can request DispatchHealth medical care via phone, mobile app, or
Read More
Haystack Oncology Launches with $56M for Post-Op Cancer Detection Tech
What You Should Know:
- Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More
Pleno Secures $40M to Disrupt Sequencing Market, Scale Multi-omics
What You Should Know:
- Pleno, Inc, a multi-omic instrument platform company revolutionizing biological target detection for clinical testing and biomedical research raises $40M in Series A funding led by Deerfield Management and Foresite Capital.
- The funding will accelerate the development of Pleno’s Hypercoding™ instrument platform, called RAPTOR ™, which is slated for early customer access in 2023 and full availability in 2024. Release below
Read More
Naveris Raises $51M for Early Detection of Viral-Driven Cancers
What You Should Know:
- Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, recently announced a $33.4M expansion of its Series A financing, bringing the total investment in Naveris to $51M.
- The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society.
Using DNA Fragmentomics Technology to Detect
Read More
Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies
What You Should Know:
- Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with $72.5M in Series A financing to pioneer novel therapies to modulate mitochondrial function.
- The financing was led by ARCH Venture Partners and Mubadala Capital with participating investors HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures, and
Read More
Pharmacogenomics: The Key to Unlocking the Future of Personalized Healthcare
Pharmacogenomics—the study of genetic influences on an individual's response to therapeutic medications—is an area of personalized medicine that is gaining momentum. Although pharmacogenomics has been around for a while, providers, health plans, pharmacists and legislators are developing a greater appreciation for its potential benefits and applications.
How Can Pharmacogenomics Improve Outcomes?
By considering a person’s DNA in treatment options, providers can determine how an
Read More
Femtech Startup Nanopath Raises $10M to Develop POC Diagnostics for Women’s Health
What You Should Know:
- Nanopath, a molecular diagnostics company enabling high-quality molecular testing in minutes raises $10M in Series A funding, co-led by co-led by Norwest Venture Partners and Medtech Convergence Fund, to develop a point-of-care diagnostics platform for women’s health screenings.
- The company plans to use the latest round of funding to support development and commercialization of Nanopath's biosensing platform that aims to transform how women's pelvic and
Read More
